Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Status:
Recruiting
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period
crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to
moderate AD.